Cite
HARVARD Citation
Drake, M. et al. (2017). Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE). International journal of clinical practice. 71 (5), p. n/a. [Online].